Tirzepatide
Dual GIP and GLP-1 Receptor Agonist
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Available as FDA-approved Mounjaro® for Type 2 diabetes and Zepbound® for weight management and obstructive sleep apnea. It provides superior weight loss and glycemic control compared to single-pathway medications through its unique dual mechanism of action.
Tirzepatide Dosing Guide
What It's Used For
Tirzepatide is a dual GIP/GLP-1 receptor agonist that revolutionizes treatment for both type 2 diabetes and weight management. It's the first medication to target both incretin pathways, providing superior results compared to single-receptor drugs.
Weight Loss (Zepbound®)
- FDA-approved for chronic weight management
- Average weight loss of 15-22% of body weight
- Also approved for obstructive sleep apnea (OSA)
Type 2 Diabetes (Mounjaro®)
- Improves glycemic control when combined with diet and exercise
- Reduces HbA1c by 2.0-2.3%
- Provides significant weight loss as secondary benefit
Metabolic Health
- Improves insulin sensitivity
- Reduces cardiovascular risk factors
- Lowers blood pressure and improves lipid profiles
Appetite Regulation
- Slows gastric emptying
- Increases satiety signals
- Reduces food cravings
How Much to Take
Starting dose — helps your body adjust
First therapeutic dose — effects begin
Continue if tolerating well
Increased efficacy
Near-maximum dose
Maximum maintenance dose
FREQUENCY
Once Weekly
Same day each week
TIMING
Any Time of Day
With or without food
DOSE INCREASE
+2.5mg
Every 4 weeks as needed
How Long to Use It
Week 4-8
2-4%
Initial Response
Appetite reduction and early weight changes become noticeable
Week 12-16
5-10%
Significant Progress
Blood sugar improvements stabilize for diabetics
Week 72
15-22%
Peak Results
Maximum weight loss achieved. Optimal metabolic benefits.
For Weight Loss
Long-term use recommended. Continue indefinitely to maintain results.
For Diabetes
Long-term use as part of your comprehensive diabetes management plan.
Important: Weight Regain Risk
Weight regain is common after discontinuation. Clinical studies show most patients regain weight within 12 months of stopping treatment. Tirzepatide is designed for long-term use.
Need-to-Know Information
How Tirzepatide Works
Dual Receptor Activation
Binds to both GIP and GLP-1 receptors simultaneously
This dual action is unique — other medications only target one receptor
Insulin Response
Triggers insulin release only when blood sugar is elevated
Glucose-dependent action reduces hypoglycemia risk
Glucagon Suppression
Reduces glucagon secretion from the pancreas
Less glucagon = less sugar released from liver
Gastric Slowing
Delays stomach emptying after meals
Food stays longer → feel full longer → eat less
Brain Signaling
Acts on appetite control centers in the brain
Reduces hunger signals and food cravings at the source
The Result
Lower blood sugar, reduced appetite, significant weight loss (15-22% in clinical trials)
Who Should Avoid It
Common Side Effects
How to Store and Inject
Before First Use
After First Use
Injection Sites
Injection Method
Injection Tips
Example Weekly Schedule
Sunday Morning
Take weekly tirzepatide injection
Monday - Saturday
Maintain regular diet and exercise routine
Next Sunday
Repeat injection at same time
If You Miss a Dose
Take it as soon as you remember
Skip missed dose, resume regular schedule
Take two doses within 3 days of each other
Tips for Best Results
Managing Side Effects
Maximize Results
Monitor Progress
Lifestyle Essentials
Expected Results Timeline
Week 4-8
2-4%
Appetite suppression begins
Week 12
5-8%
Visible weight loss
Week 24
10-15%
Substantial results
Week 52-72
15-22%
Maximum achieved
Serious Warning — Seek Immediate Medical Attention If:
Medical Disclaimer
Tirzepatide is FDA-approved as Mounjaro® for Type 2 diabetes and Zepbound® for chronic weight management. This information is for educational purposes and should not replace consultation with healthcare providers. Individual results may vary. Prescribing information and medical supervision are required for all therapeutic uses.